Maya K. Leabman
46 works · 8,043 citations · h-index 19
Top works
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- Natural variation in human membrane transporter genes reveals evolutionary and functional constraints
- A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.
- Transporters involved in the elimination of drugs in the kidney: Organic anion transporters and organic cation transporters
- Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1
- Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function
- Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates
- Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin
- Amelioration of Type 2 Diabetes by Antibody-Mediated Activation of Fibroblast Growth Factor Receptor 1
- Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor
- Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants
- Interactions of n-Tetraalkylammonium Compounds and Biguanides with a Human Renal Organic Cation Transporter (hOCT2)
- Estimating the contribution of genes and environment to variation in renal drug clearance
- Functional genomics of membrane transporters in human populations
- Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1)
- Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys
- Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade
- A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies
- PharmGKB Update: I. Genetic Variants of the Organic Cation Transporter 2 (OCT2, SLC22A2)
- Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9